In Brief: Vitamix Expands, No “Probiotic” In E.U. Ads, Mylan Misses On Meda, Akorn Hits On VersaPharm
This article was originally published in The Tan Sheet
Executive Summary
Vitamix triples manufacturing space; using ‘probiotic’ not allowed in E.U.; Meda rejects Mylan bids; Akorn acquires VersaPharm; La. blocks DXM sales to minors; and more news In Brief.
You may also be interested in...
Mylan Bids Nearly $30 Billion For Perrigo In Generic Market Consolidation Move
Perrigo receives an unsolicited offer from Mylan for almost $30 billion in cash and stock, the firms say. The deal, which would create an OTC, nutritional product and generic Rx drug firm with 2014 revenue of $15.3 billion, could launch a bidding war with other firms vying for Dublin-based Perrigo, say analysts.
Mylan Bids Nearly $30 Billion For Perrigo In Generic Market Consolidation Move
Perrigo receives an unsolicited offer from Mylan for almost $30 billion in cash and stock, the firms say. The deal, which would create an OTC, nutritional product and generic Rx drug firm with 2014 revenue of $15.3 billion, could launch a bidding war with other firms vying for Dublin-based Perrigo, say analysts.
Industry News Roundup
Nexium 24HR Sample Pack Approved; Boots Protection Claims Imply Prevention; Support of Philosophy serum is “inherently arbitrary,” NAD said; Nestle Formula Comparative Claims Apply Across Entire Category; Happy consumers OK for U.K. e-cig ads; Manzo Scouts Probiotic Path At FDA and Ingredion acquires Penford.